4种非小细胞肺癌二线药物治疗方案费用比较研究

目的:对多西他赛、培美曲塞、吉非替尼和厄洛替尼等4种非小细胞肺癌二线药物治疗方案的费用进行比较。方法:基于专家咨询获得的关于中国晚期非小细胞肺癌二线治疗医疗资源使用信息,应用微观模拟法测算4种非小细胞肺癌二线药物治疗方案的费用。结果:多西他赛、吉非替尼、培美曲塞、厄洛替尼方案的每周期(3周)费用分别为12237.02、12102.82、27614.93、14272.76元。结论:对非小细胞肺癌二线药物治疗预期无进展生存期达到6个月以上的患者,选择吉非替尼方案在药物经济学上类似于多西他赛。

Comparison of the Cost of 4 Kinds of Second-line Drug Treatment Regimes for Non-small Cell Lung Cancer

OBJECTIVE：To compare the cost of 4 kinds of second-line drug treatment regimes（docetaxel, pemetrexed, gefitinib,and erlotinib）for non-small-cell lung cancer（NSCLC）. METHODS： The utilization information of medical resources in the NSCLC treatment regimes was collected from experts who were familiar with NSCLC treatment. The costs of 4 kinds of second-line drug treatment regimes were calculated using micro-simulation method. RESULTS： The costs of every cycle period（3 weeks）were 12 237.02 yuan for docetaxel regime, 12 102.82 yuan for gefitinib, 27 614.93 yuan for pemetrexed and 14 272.76 yuan for erlotinib. CONCLUSION： Gifitinib is not inferior to docetaxel in terms of pharmaeconomics for those with 6 months or longer period of anticipated progression-free survival.